The Chinese government's intense desire for technological self-sufficiency and global leadership paradoxically reduces investment risk. Beijing now "desperately" needs its deep science companies to succeed, making another unpredictable, Jack Ma-style crackdown on the industry less likely than in previous years.

The XBI is at post-pandemic highs, but this isn't a true reflection of the entire sector. Its methodology shifted from an equal-weight index to one favoring larger, liquid companies. Recent M&A of these larger companies has disproportionately driven the index up, masking the performance of smaller biotechs.

Contrary to her buy-and-hold reputation, Cathie Wood is actively managing risk by selling shares of top performers like Roku. She is reallocating that capital into out-of-favor Chinese tech companies like Alibaba and Baidu, signaling a tactical portfolio rotation despite geopolitical risks.

China's share of innovative biotech deals surged from <5% to 40%+. The core reason is a labor arbitrage: with just as many smart scientists who get paid less, and research being predominantly manual, China produces more experimental data per dollar, giving them a significant edge.

Following a 30-40% valuation surge in 2025, China's market is expected to stabilize. Further upside in 2026 will depend on corporate earnings, projected at a modest 6%, signaling a shift from a valuation-driven to an earnings-driven market that requires a different investment approach.

While China's high-tech manufacturing output soars (up 9.4%), retail sales lag significantly (up only 3.7%). This stark divergence reveals a fundamentally imbalanced economy that excels at production but fails to distribute wealth to its citizens, suppressing domestic demand and risking a future crash.

Onshore Chinese stocks (A-shares) are outperforming due to their concentration in upstream manufacturing, which benefits from the end of producer price deflation. In contrast, offshore markets (H-shares) are dragged down by underperforming, heavyweight internet stocks, creating a significant performance gap.

Contrary to typical risk-off behavior, the biotech index (XBI) is outperforming the S&P 500. It shows resilience on down days and outsized gains on up days. This indicates a persistent underlying investor demand for the sector, possibly due to its multi-year underperformance and maturing fundamentals.

The old narrative of China's IP theft is outdated. Today, China's competitive advantage in sectors like biotech comes from its massive scale, significant resources, and collective lack of profit sensitivity. This combination allows it to dominate industries and destroy profitability for other global players, as previously seen in solar and EVs.